FDA agrees to review Preos drug application

Salt Lake-based NPS Pharmaceuticals Inc. said Monday that the U.S. Food and Drug Administration has accepted for review the company's new drug application to market Preos for the treatment of osteoporosis in postmenopausal women.

NPS submitted the application in May and the FDA has determined that the application is sufficiently complete to permit a substantive review.

A similar application to market Preos in Europe under the brand name Preotact is under review by the European Medicines Agency.